Table 2.

Effects of apigenin, myricetin or their combination on serum oxidative stress biomarkers.

Parameters Drugs	Serum GSH Level (μmol/mL)	Serum MDA Level (n mol/mL)	Serum catalase Activity(U/mL)
Control	3.47 ± 0.14	10.48 ± 0.43	15.67 ± 0.309
Apigenin	3.2 ± 0.15	10.53 ± 0.44	15.36 ± 0.34
Myricetin	3.42 ± 0.12	8.92 ± 0.26	15.53 ± 0.37
Apigenin + Myricetin	3.89 ± 0.14	7.22 ± 0.18	16.22 ± 0.32
Cisplatin	0.91 ± 0.037*	25.3 ± 1.51*	4.23 ± 0.232*
Cisplatin + Apigenin	1.7 ± 0.09a	17.8 ± 0.37a	9.05 ± 0.29a
Cisplatin + Myricetin	2.21 ± 0.16a	14.3 ± 0.24a	10.24 ± 0.39a
Cisplatin + Apigenin + Myricetin	2.89 ± 0.78a,b	11.28 ± 0.29a,b,c	12.42 ± 0.34a,b,c

Data were expressed as mean ± SEM (n = 6–8).

^*Significantly different from the normal control group at p < 0.05.

^aSignificantly different from cisplatin group at p < 0.05.

^bSignificantly different from apigenin group at p < 0.05.

^cSignificantly different from myricetin group at p < 0.05.